United States Liver Cancer Therapeutics Market is Expected to be Dominated by the Chemotherapy Segment through 2028
During the forecast period, the growing incidences of liver cancer is
anticipated to fuel expansion in the United States liver cancer therapeutics
market.
According to TechSci Research report, “United
States Liver Cancer Therapeutics - By Region, Forecast and Opportunities, 2018-2028”,
The United States liver cancer therapeutics market is expected to grow at an
impressive rate owing to several factors. These factors include the increasing
prevalence of liver cancer, rising demand for effective treatments, and
advancements in targeted therapies and immunotherapies.
The incidence of liver cancer is expected to
increase as the population ages since age raises the chance of acquiring liver
cancer. As more people develop liver cancer, the market for liver cancer
therapeutics is expected to expand as patients look for efficient treatments
to enhance their prognosis.
The market of liver cancer
therapeutics in the United States, however, confronts several challenges.
The high cost of liver cancer therapies, which can be an enormous burden for
patients and healthcare systems, is one of the key issues. Furthermore, the
creation of innovative liver cancer therapies is a difficult, expensive, and
time-consuming process, which can be a barrier to innovation in this sector.
Despite these challenges, the market
of liver cancer therapeutics in the United States is anticipated to expand
over the coming years, supported by several trends. Precision medicine,
which involves adjusting treatment to the unique features of each patient's tumor,
is one of the major market trends. Using more effective and individualized
treatments, precision medicine has the potential to enhance patient outcomes.
The United States liver cancer therapeutics
market is expanding as an outcome of technological improvements. For
instance, improvements in imaging technology have made it possible to diagnose
liver cancer more accurately and earlier, which can result in earlier treatment
and better patient outcomes. Additionally, improvements in drug delivery
technologies, like liposomes and nanoparticles, have the potential to increase
the efficacy and security of therapeutics for liver cancer.
The United States liver cancer therapeutics
market has also been significantly impacted by the COVID-19 pandemic. The
pandemic has hampered clinical trials and research initiatives, delaying
the development and release of novel liver cancer therapeutics. The pandemic
has also resulted in decreased patient access to medical services, delaying the
detection, and treatment of patients with liver cancer.
Browse over XX Market Data Figures spread through XX Pages and an in-depth TOC on "United States Liver Cancer Therapeutics Market."
The United States liver cancer therapeutics
market can be segmented by cancer type, therapy, equipment, factors, route of
administration, distribution channel, and region.
Based on therapy, the market can be segmented
into targeted therapy, chemotherapy and radiation therapy, immunotherapy, and
others. In the years to come, the United
States for liver cancer therapeutics market is expected to be dominated by
chemotherapy for several key reasons. For many years, the mainstay of treatment
for many patients with liver cancer has been chemotherapy. Chemotherapy
medications can be administered in several methods, such as intravenous
infusion or oral medication, and are intended to either kill cancer cells or
limit their growth. To provide liver cancer patients with the best outcomes,
chemotherapy can be combined with other therapies such surgery, radiation
therapy, and targeted therapy. For patients with advanced liver cancer or tumors
that cannot be directly removed, this multifaceted strategy is very crucial.
In terms of distribution channel, the market
can be divided into hospital pharmacies, retail pharmacies, and online
pharmacies. Hospital pharmacies are expected to dominate the liver cancer
therapeutics market in the United States in the coming years for a variety
of factors. One of the primary causes is that therapeutics used to treat
liver cancer at times involve advanced and specialized procedures requiring
close medical supervision and control. Compared to retail or specialty
pharmacies, hospitals are better suited to manage these therapies and give
patients the support they need. Hospitals also often act as the primary
facility for patients with liver cancer to obtain their diagnosis, therapy, and
post-treatment care. For liver cancer patients, hospital pharmacists may offer
an integrated system of care, ensuring that they receive the treatment they
require and the support they need along the way.
Based on the region, the market can be
classified into the following categories, North-East, Mid-West, South, and West.
North-East region will dominate the United States liver cancer therapeutics
market in the coming years because North-East region is home to several
top-ranked hospitals and research institutions.
Major companies operating in United States liver
cancer therapeutics market include:
- Bristol-Myers Squibb
- Merck & Co.
- Bayer AG
- Eli Lilly and Company
- Novartis International AG
- Ipsen Biopharmaceuticals Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“Owing to the rising incidence of liver cancer
and the development of cutting-edge treatments, the United States liver cancer
therapeutics market is expanding significantly. Liver cancer is a serious
and often fatal disease that affects a significant number of people in the
United States. Clinical studies examining new and potential liver cancer
therapeutics, such as immunotherapy, targeted therapy, and combination
therapies, have increased because of the prevalence of liver cancer. The goals
of these trials are to enhance patient outcomes and lessen the adverse
consequences of traditional therapeutics like chemotherapy. The liver cancer
therapies market is anticipated to benefit even more from technology
developments like gene therapy and precision medicine in the years to come.”
said Mr. Karan Chechi, Research Director with TechSci Research, a research-based
global management consulting firm.
“United States Liver Cancer Therapeutics
Market, By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma,
Hepatoblastoma, Angiosarcoma, and Liver Metastasis), By Therapy (Targeted
Therapy, Chemotherapy and Radiation Therapy, Immunotherapy, and Others), By
Equipment (Computed Radiography, Sonography, MRI, and Others), By Factors
(Cirrhosis, Nonalcoholic Fatty Liver Disease, Excessive Alcohol Consumption,
and Others), By Route of Administration (Oral, Intravenous, and Others), By Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By
Region, Competition, Forecast and Opportunities, 2028”, has evaluated the future growth potential of United
States liver cancer therapeutics market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in United States liver cancer therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com